IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v24y2006i3p1-3.html
   My bibliography  Save this article

Medicaid Preferred Drug Lists: Cost Containment and Side Effects

Author

Listed:
  • Alvin Headen

Abstract

No abstract is available for this item.

Suggested Citation

  • Alvin Headen, 2006. "Medicaid Preferred Drug Lists: Cost Containment and Side Effects," PharmacoEconomics, Springer, vol. 24(3), pages 1-3, December.
    • Handle: RePEc:spr:pharme:v:24:y:2006:i:3:p:1-3
    DOI: 10.2165/00019053-200624003-00001
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200624003-00001
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200624003-00001?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Tamer Abdelgawad & Lisa Egbuonu-Davis, 2006. "Preferred Drug Lists and Medicaid Prescriptions," PharmacoEconomics, Springer, vol. 24(3), pages 55-63, December.
    2. Alvin Headen & Neal Masia & Kirsten Axelsen, 2006. "Effects of Medicaid Access Restrictions on Statin Utilisation for Patients Treated by Physicians Practising in Poor and Minority Neighbourhoods," PharmacoEconomics, Springer, vol. 24(3), pages 41-53, December.
    3. David Ridley & Kirsten Axelsen, 2006. "Impact of Medicaid Preferred Drug Lists on Therapeutic Adherence," PharmacoEconomics, Springer, vol. 24(3), pages 65-78, December.
    4. Jonathan Ketcham & Andrew Epstein, 2006. "Which Physicians are Affected Most by Medicaid Preferred Drug Lists for Statins and Antihypertensives?," PharmacoEconomics, Springer, vol. 24(3), pages 27-40, December.
    5. Frank Lichtenberg, 2006. "The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003," PharmacoEconomics, Springer, vol. 24(3), pages 5-25, December.
    6. Lisa Mucha & Neal Masia & Kirsten Axelsen, 2006. "Per-patient-per-month Drug Costs in Medicare Part D Protected Classes," PharmacoEconomics, Springer, vol. 24(3), pages 79-84, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Apostolos Tsiachristas† & Ren頇oudriaan & Wim Groot, 2013. "The welfare effects of innovative pharmaceuticals: an international perspective from the Dutch experience," Applied Economics, Taylor & Francis Journals, vol. 45(9), pages 1219-1226, March.
    2. Karine Lamiraud & Stephane Lhuillery, 2016. "Endogenous Technology Adoption and Medical Costs," Health Economics, John Wiley & Sons, Ltd., vol. 25(9), pages 1123-1147, September.
    3. Vincenzo Atella & Joanna Kopinska, 2012. "The impact of cost sharing schemes on drug compliance: evidence based on quantile regression," CEIS Research Paper 247, Tor Vergata University, CEIS, revised 27 Jul 2012.
    4. Karine Lamiraud & Stéphane Lhuillery, 2015. "Endogenous Technology Adoption and Medical Costs," Working Papers hal-01218064, HAL.
    5. Maclean Johanna Catherine & Cook Benjamin & Carson Nicholas & Pesko Michael F, 2019. "Public Health Insurance and Prescription Medications for Mental Illness," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 19(1), pages 1-25, January.
    6. de Meijer, Claudine & O’Donnell, Owen & Koopmanschap, Marc & van Doorslaer, Eddy, 2013. "Health expenditure growth: Looking beyond the average through decomposition of the full distribution," Journal of Health Economics, Elsevier, vol. 32(1), pages 88-105.
    7. Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
    8. Natt Hongdilokkul & Emanuel Krebs & Xiao Zang & Haoxuan Zhou & Fahmida Homayra & Jeong Eun Min & Bohdan Nosyk, 2021. "The effect of British Columbia's Pharmacare coverage expansion for opioid agonist treatment," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1222-1238, May.
    9. David B. Ridley, 2015. "Payments, Promotion, And The Purple Pill," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 86-103, January.
    10. Michel Dumont & Peter Willemé, 2013. "Working Paper 02-13 - Machines that go ‘ping’: medical technology and health expenditures in OECD countries," Working Papers 1302, Federal Planning Bureau, Belgium.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:24:y:2006:i:3:p:1-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.